Sarah Cannon, the Cancer Institute of Hospital Corporation of America (HCA), today announced that Genospace, LLC, a cloud-based software company focused on advancing personalized medicine, will merge with its organization and become a wholly-owned subsidiary. By joining forces, Sarah Cannon and Genospace will harness and use molecular profiling data to more effectively match cancer patients to cutting-edge therapies in clinical trials.
Sarah Cannon and Genospace, LLC Announce Merger to Enhance Cancer Care Through Personalized Medicine Platform
Researchers at the UCLA Center for Autism Research and Treatment have identified a signature brain-wave pattern for children with autism spectrum disorder related to a genetic condition known as Dup15q syndrome. The research team noted that this signature is among the first quantitative biomarkers identified in electroencephalogram tests discovered for any syndrome highly associated with autism spectrum disorder.
AbbVie (NYSE: ABBV), a global biopharmaceutical company, life-sciences startup Genomics Medicine Ireland Limited (GMI), and WuXi NextCODE, the global contract genomics organisation, today announced the launch of a long-term strategic alliance to conduct population genomics research in Ireland aimed at advancing the discovery and development of novel therapeutic approaches to a range of serious diseases. The 15-year collaboration will focus on major chronic diseases within oncology, neuroscience and immunology that affect hundreds of thousands of people in Ireland and hundreds of millions worldwide. Financial terms were not disclosed.
Biodesix and Bioyong Announce Agreement for Joint Development and Commercialization of VeriStrat Test in Greater China
Biodesix, Inc. (Boulder, CO, USA) and Bioyong Technology Company Ltd. (Beijing, China) announced today that they have entered into an international collaboration agreement where Bioyong will develop and commercialize a version of Biodesix’s VeriStrat® proteomic blood test, a precision medicine diagnostic for patients with non-small cell lung cancer (NSCLC), for clinical use in Greater China, with potential expansion into other Asia-Pacific countries.
Habit, the world’s first complete personalized nutrition company, today announced that customers in the Bay Area can now order the at-home Nutrition Test Kit to uncover what their biology craves. Starting January 4th, 2017, residents in the Bay Area will be able to go to Habit.com to place their orders. Residents outside of the Bay Area who are interested in the test kits will be added to a waiting list and contacted when the kits are available in their area.